BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 34684168)

  • 21. Genetic-guided Risk Assessment and Management of Thyroid Cancer.
    Xing M
    Endocrinol Metab Clin North Am; 2019 Mar; 48(1):109-124. PubMed ID: 30717896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms.
    Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
    World J Surg; 2006 May; 30(5):767-74. PubMed ID: 16547620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
    Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation profiles of follicular thyroid tumors by targeted sequencing.
    Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
    Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of CXCR4 and SDF-1 in differentiated thyroid cancer depends on CD8+ density.
    Wilhelm A; Lemmenmeier I; Lalos A; Posabella A; Kancherla V; Piscuoglio S; Delko T; von Flüe M; Glatz K; Droeser RA
    BMC Endocr Disord; 2022 Nov; 22(1):292. PubMed ID: 36419107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
    Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
    Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment.
    Gianoukakis AG; Giannelli SM; Salameh WA; McPhaul LW
    Mol Cell Endocrinol; 2011 Jan; 332(1-2):9-20. PubMed ID: 21094678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biological markers in thyroid tumors].
    Matsuo SE; Martins L; Leoni SG; Hajjar D; Ricarte-Filho JC; Ebina KN; Kimura ET
    Arq Bras Endocrinol Metabol; 2004 Feb; 48(1):114-25. PubMed ID: 15611824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
    Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
    Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
    Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
    Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Stratification Using a Novel Genetic Classifier Including
    Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
    Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
    [No Abstract]   [Full Text] [Related]  

  • 32. Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.
    Geraldo MV; Kimura ET
    PLoS One; 2015; 10(11):e0141726. PubMed ID: 26536459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long Non-Coding RNA ZFAS1 as a Novel Potential Biomarker for Predicting the Prognosis of Thyroid Cancer.
    Han CG; Huang Y; Qin L
    Med Sci Monit; 2019 Apr; 25():2984-2992. PubMed ID: 31012438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive value of circular RNAs in the diagnosis, prognosis and clinicopathological features of thyroid cancer: A systematic review and meta-analysis.
    Zhu C; Feng Z; Hong F; Sun H; Wang Z; Zhao Z; Zhang F
    Pathol Res Pract; 2022 Aug; 236():153871. PubMed ID: 35797852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
    Romei C; Elisei R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer stem-like cells and thyroid cancer.
    Guo Z; Hardin H; Lloyd RV
    Endocr Relat Cancer; 2014 Oct; 21(5):T285-300. PubMed ID: 24788702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Key Genes in Thyroid Cancer Microenvironment.
    Zhao K; Yang H; Kang H; Wu A
    Med Sci Monit; 2019 Dec; 25():9602-9608. PubMed ID: 31839674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome.
    Heikkilä A; Hagström J; Mäenpää H; Louhimo J; Siironen P; Heiskanen I; Haglund C; Arola J
    Thyroid; 2013 Apr; 23(4):456-65. PubMed ID: 23106428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.
    Xu B; David J; Dogan S; Landa I; Katabi N; Saliba M; Khimraj A; Sherman EJ; Tuttle RM; Tallini G; Ganly I; Fagin JA; Ghossein RA
    Histopathology; 2022 Jan; 80(2):322-337. PubMed ID: 34449926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.